Skip to Content

Cardiotoxicity in BRAF/MEK-Treated Melanoma: A Manageable but Underrecognized Risk

BRAF/MEK inhibitors improve survival in metastatic melanoma but carry a significant risk of cardiotoxicity. Our real-world study found a 21% incidence of LVEF-reduction in a Danish patient cohort, primarily within the first year. Most cases were reversible, underscoring the need for monitoring and individualized management.

Get access

If you are a doctor or other health professional, you can access the entire article by creating a profile on BestPractice Nordic.

Back to top